IFNA1 and hepatocellular carcinoma: The interval from the end of IFN therapy to the detection of HCC was 20–240 months (mean, approximately 7.8 years) in the SVR-HCC patients, which was similar to the time from IFN therapy to the second biopsy in the SVR-non-HCC patients (38–199 months; mean, approximately 7.2 years).